Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06575426 | NOT YET RECRUITING | Diabetes Mellitus, Type 1

A Study to Investigate Safety and Effectiveness of Pancreatic Cells Derived From Pigs (OPF-310) in Patients With Type 1 Diabetes Mellitus
Sponsor:

Otsuka Pharmaceutical Factory, Inc.

Brief Summary:

This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.

Condition or disease

Diabetes Mellitus, Type 1

Hypoglycemia

Intervention/treatment

OPF-310

Phase

PHASE1

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 13 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus
Actual Study Start Date : 2024-12-28
Estimated Primary Completion Date : 2027-06-30
Estimated Study Completion Date : 2027-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 35 Years to 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Subject must be aged 35 to 65 years of age inclusive, at the time of signing the informed consent.
  • 2. Subject has an established diagnosis of type 1 diabetes mellitus (T1DM)(in accordance with the American Diabetes Association's criteria), with a minimum duration since diagnosis of 5 years.
  • 3. Subject has unstable T1DM, not achieving adequate control after receiving closed loop system (continuous glucose monitoring (CGM): Dexcom G6, insulin pump: Omnipod® 5 or t:slim X2) under care of a qualified diabetes team for at least 6 months prior to enrollment.
  • 4. Subject has had a Level 3 (severe) hypoglycemic episode (defined as having cognitive impairment requiring external assistance for recovery) at least three times within the 1 year prior to enrollment recorded in the medical record or patient log.
  • 5. Subject has C-peptide \<0.3 ng/mL following a mixed meal tolerance test or undetectable fasting C-peptide.
  • 6. Hemoglobin A1C (HbA1c) ≥ 7.5 and ≤ 9.0
  • 7. Contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • 8. Subject who can agree to cooperate with lifetime follow-up after transplantation.
  • 9. Subject is capable of providing signed informed consent
Exclusion Criteria
  • 1. Previous history of insulin resistance (defined as an average insulin dose requirement ≥ 0.8 unit/kg/day for 1 week prior to enrollment).
  • 2. Subject has latent autoimmune diabetes in adults (LADA), ketosis-prone (Flatbush) diabetes, or maturity onset diabetes of the young (MODY).
  • 3. CRP ≥ 10 mg/L.
  • 4. Clinically unstable thyroid disease (thyroid stimulating hormone (TSH)\< the lower limit of the normal range of TSH at the site.) Patients with subclinical hyperthyroidism can be rescreened once TSH levels normalize due to treatment or other factors. In addition, patients with transiently abnormal TSH levels may undergo rescreening only once during the screening period.
  • 5. History of malignancies within the past 5 years, excluding basal and squamous cell carcinoma
  • 6. Positive serologies or nucleic acid testing for human immunodeficiency virus (HIV), hepatitis C, and hepatitis B.
  • 7. Active or untreated proliferative diabetic retinopathy. Subjects may be rescreened once they are successfully treated.
  • 8. Serious comorbid conditions that are likely to affect participation in the study, including
    • 1. Within the last 12 months, peripheral vascular disease with previous amputation.
    • 2. History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation.
    • 3. Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalization for decompensation; a requirement for mechanical ventilation at any stage; or long- term treatment with oral corticosteroids.
    • 4. Macroalbuminuria (\> 300 mg albumin/gm creatinine).
    • 5. Estimated glomerular filtration rate (eGFR) cut-off of \< 30 ml/min for all per Kidney Disease Improving Global Outcomes (KDOQI) and Kidney Disease Outcomes Quality Initiative (KDIGO) consensus.
    • 9. Use of warfarin or other anticoagulant therapy (except aspirin), or prothrombin time and international normalized ratio (PT-INR) \> 1.5
    • 10. Adrenal insufficiency being treated with corticosteroids
    • 11. Previous pan-peritonitis
    • 12. Previous cardiovascular or cerebrovascular disease
    • 13. Patients with hematopoietic stem cell abnormalities (e.g., aplastic anemia, myelodysplastic syndrome)
    • 14. Patients who received a blood transfusion in the previous 90 days, are anticipated to undergo surgery during the 1-year study period that may require transfusion, or have donated blood within the previous 90 days.
    • 15. Previous receipt of an organ, skin allograft, or other tissue transplant from an allogeneic human or animal donor.
    • 16. Treatment with immunosuppressive medication.
    • 17. Previous abdominal surgery, excluding uncomplicated appendectomy, cholecystectomy, exploratory laparoscopy and hernia repair performed prior to 12 weeks prior to enrollment.
    • 18. Treatment with any non-insulin hypoglycemic medication not intended to be used as an adjunct to insulin therapy.
    • 19. Treatment with acetaminophen or hydroxycarbamide.
    • 20. Use of any investigational products within 12 weeks of enrollment (before entering run-in) or 5 half-lives of the investigational product, whichever is greater.
    • 21. Subject has history of allergy to antibiotics (Amphotericin B, Cefazolin, Ciprofloxacin, Gentamicin), which are used during manufacture of OPF-310.
    • 22. Previous history of insulin allergy (including porcine insulin), pork product allergy or alginate/seaweed allergy.
    • 23. Panel reactive antibodies (PRA) \> 80 %.
    • 24. Active drug, substance or alcohol addiction.
    • 25. Body mass index (BMI) \>27 kg/m2.
    • 26. Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol, including dementia, psychiatric disorder, medical condition, or a history of non-adherence to appointments or treatments
A Study to Investigate Safety and Effectiveness of Pancreatic Cells Derived From Pigs (OPF-310) in Patients With Type 1 Diabetes Mellitus

Location Details

NCT06575426

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found